PPARGC1A and melanoma: Inhibition of BRAF mutations using MAPK inhibitors suppresses glycolysis [60] leading to temporarily suppression of melanoma growth, but also promotes metabolic switch to OXPHOS phenotype via induction of MITF and PGC1α expression [17, 18, 19, 20, 51].